BibTex RIS Kaynak Göster

Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri

Yıl 2011, Cilt: 11 Sayı: 4, 160 - 169, 01.10.2011
https://doi.org/10.5222/j.child.2011.160

Öz

Amaç: Kemoterapi almakta olan ve tedavisi kesilmiş akut lenfoblastik lösemili çocuklarda immünitenin önemli elemanı NK hücrelerinde kemoterapi ile değişiklikler oluşabilir. Yöntemler: Yaşları 2 ile 19 arasında değişen otuz üç ALL’li çocuk hasta immünfenotipleri, risk grupları ve klinik özellikleri kaydedilerek grup 1 ALL TRALL 2000 protokolüne göre protokol M’i bitirmiş , grup 2 idame kemoterapisi alan ve grup 3 tedavisi kesilmiş olarak sınıflandırıldı. Kontrol grubu grup 4 ise 2 ile 13 yaşları arasındaki on bir sağlıklı çocuktan oluşturuldu. Hasta ve kontrol grubundan bilgilendirilmiş onam ile alınan kan örneklerinde NK sitotoksisite deneyi, NK alt gruplarının flow sitometri ile tayini, sitokin ölçümü yapıldı, litik ünite hesaplandı ve sonuçlar hastaların klinik özellikleri ile birlikte değerlendirildi. SPSS 14.0 ile “oneway ANOVA” testi kullanılarak analiz edildi. Bulgular: Grup 2’nin 1: 1 E: H oranında NK sitotoksisitesi diğer gruplardan anlamlı derecede yüksekti p

Kaynakça

  • 1. Pui CH, Campana D. Childhood Leukemia. in: Abeloff M, Armitage JO, Niederhuber JE, Kastan MB, McKenna WB(eds). Abeloff: Abeloff’s Clinical Oncology, 4th ed. Churchill Livingstone, An Imprint of Elsevier, 2008.
  • 2. Wehinger H&Karitzky D. T and B lymphocytes before, during, and after cytostatic therapy of acute lymphoblastic leukemia (ALL) in children. Klinische Paediatrie 1977; 189:234-41. PMid:301585
  • 3. Miller JS. The biology of natural killer cells in cancer, infection and pregnancy. Experimental Hematology 2001;29:1157- 68. http://dx.doi.org/10.1016/S0301-472X(01)00696-8
  • 4. Sørskaar D, Førre O, Lie SO. Natural Killer Cell Activity of Peripheral Blood and Bone Marrow Mononuclear Cells from Patients with Childhood Acute Lymphoblastic Leukemia. Acta Paediatr Scand 1985;74:433-7. http://dx.doi.org/10.1111/j.1651-2227.1985.tb10998.x
  • 5. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1(1):51-63. http://dx.doi.org/10.1007/BF00915477 PMid:7334070
  • 6. Mazur B, Olejnik I, Wylezol I, Sonta-Jakimczyk D, Szczepanski T, Karpe J. Assessment of chosen parameters of the immune system in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003;20(4):303-8. PMid:12746162
  • 7. Ekert H, Jose DG. Letter: Chemotherapy and B.C.G. in acute lymphocytic leukaemia. Lancet 1975;11(7937):713-4. http://dx.doi.org/10.1016/S0140-6736(75)90818-1
  • 8. Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11(3):281-92. http://dx.doi.org/10.3109/08880019409141671
  • 9. Jermy A, Lilleyman JS, Jennings R, Rees RC. Spontaneous natural killer cell activity in childhood acute lymphoblastic leukaemia. Eur J Cancer Clin Oncol 1987;23(9):1365-70. http://dx.doi.org/10.1016/0277-5379(87)90121-0
  • 10. Aricò M, Lanfranchi A, Molinari E, Maccario R, Nespoli L, Burgio GR. Cell-mediated cytotoxicity in children during and after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1988;5(4):279-86. http://dx.doi.org/10.3109/08880018809037367
  • 11. Abo T, Cooper MD, Balch CM. Postnatal expansion of the natural killer and killer cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med 1982;155(1):321- 6. http://dx.doi.org/10.1084/jem.155.1.321 PMid:7054358
  • 12. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Br J Haematol 2009;147(3):360-70. Epub 2009 Aug 19. http://dx.doi.org/10.1111/j.1365-2141.2009.07862.x PMid:19694715
  • 13. V.P.C.P. de Toledo et al. Natural Killer Cells: Deciphering Their Role, Diversity and Functions. in: Zimmer J (editor). Natural killer cells. Springer-Verlag Berlin Heidelberg 2010:1- 38. http://dx.doi.org/10.1007/978-3-642-02309-5_1
  • 14. Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005;44(5):461-8. http://dx.doi.org/10.1002/pbc.20255
  • 15. Kovacs GT, Barany O, Schlick B, et al. Late immune recovery in children treated for malignant diseases. Pathol Oncol Res 2008;14(4):391-7. Epub 2008 Jun 25. http://dx.doi.org/10.1007/s12253-008-9073-5

The Impact of Chemotherapy on Natural Killer Cells in Children with Acute Lymphoblastic Leukemia

Yıl 2011, Cilt: 11 Sayı: 4, 160 - 169, 01.10.2011
https://doi.org/10.5222/j.child.2011.160

Öz

Objective: Chemotherapy may induce changes in NK cells which are important componnets of the immune system in children with acute lymphoblastic leukemia who are are on chemotherapy or have completed therapy.Methods: Thirty three children aged between 2 and 19 were included in the study. Their immunophenotypes, related risk groups, and clinical characteristics were recorded. According to ALL TRALL 2000 protocol patients were classified into three groups: Group 1 patients who fulfilled requirements of protocol M , Group 2 patients still on maintenance chemotherapy and Group 3 patients who completed therapy . Control group group 4 consisted of eleven healthy children aged between 2 and 13. NK cytotoxicity test, flow cytometric analysis of NK subgroups, cytokine analysis were performed in blood samples taken with informed consent from parents of the patients and the controls. Clinical characteristics of the patients were evaluated based on these results. Analysis was performed with “one way ANOVA” statistical test using SPSS 14.0. Results: In 1: 1 E: T ratio, Group 2’s NK cytotoxicity was significantly higher than any other group p

Kaynakça

  • 1. Pui CH, Campana D. Childhood Leukemia. in: Abeloff M, Armitage JO, Niederhuber JE, Kastan MB, McKenna WB(eds). Abeloff: Abeloff’s Clinical Oncology, 4th ed. Churchill Livingstone, An Imprint of Elsevier, 2008.
  • 2. Wehinger H&Karitzky D. T and B lymphocytes before, during, and after cytostatic therapy of acute lymphoblastic leukemia (ALL) in children. Klinische Paediatrie 1977; 189:234-41. PMid:301585
  • 3. Miller JS. The biology of natural killer cells in cancer, infection and pregnancy. Experimental Hematology 2001;29:1157- 68. http://dx.doi.org/10.1016/S0301-472X(01)00696-8
  • 4. Sørskaar D, Førre O, Lie SO. Natural Killer Cell Activity of Peripheral Blood and Bone Marrow Mononuclear Cells from Patients with Childhood Acute Lymphoblastic Leukemia. Acta Paediatr Scand 1985;74:433-7. http://dx.doi.org/10.1111/j.1651-2227.1985.tb10998.x
  • 5. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1(1):51-63. http://dx.doi.org/10.1007/BF00915477 PMid:7334070
  • 6. Mazur B, Olejnik I, Wylezol I, Sonta-Jakimczyk D, Szczepanski T, Karpe J. Assessment of chosen parameters of the immune system in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003;20(4):303-8. PMid:12746162
  • 7. Ekert H, Jose DG. Letter: Chemotherapy and B.C.G. in acute lymphocytic leukaemia. Lancet 1975;11(7937):713-4. http://dx.doi.org/10.1016/S0140-6736(75)90818-1
  • 8. Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11(3):281-92. http://dx.doi.org/10.3109/08880019409141671
  • 9. Jermy A, Lilleyman JS, Jennings R, Rees RC. Spontaneous natural killer cell activity in childhood acute lymphoblastic leukaemia. Eur J Cancer Clin Oncol 1987;23(9):1365-70. http://dx.doi.org/10.1016/0277-5379(87)90121-0
  • 10. Aricò M, Lanfranchi A, Molinari E, Maccario R, Nespoli L, Burgio GR. Cell-mediated cytotoxicity in children during and after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1988;5(4):279-86. http://dx.doi.org/10.3109/08880018809037367
  • 11. Abo T, Cooper MD, Balch CM. Postnatal expansion of the natural killer and killer cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med 1982;155(1):321- 6. http://dx.doi.org/10.1084/jem.155.1.321 PMid:7054358
  • 12. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Br J Haematol 2009;147(3):360-70. Epub 2009 Aug 19. http://dx.doi.org/10.1111/j.1365-2141.2009.07862.x PMid:19694715
  • 13. V.P.C.P. de Toledo et al. Natural Killer Cells: Deciphering Their Role, Diversity and Functions. in: Zimmer J (editor). Natural killer cells. Springer-Verlag Berlin Heidelberg 2010:1- 38. http://dx.doi.org/10.1007/978-3-642-02309-5_1
  • 14. Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005;44(5):461-8. http://dx.doi.org/10.1002/pbc.20255
  • 15. Kovacs GT, Barany O, Schlick B, et al. Late immune recovery in children treated for malignant diseases. Pathol Oncol Res 2008;14(4):391-7. Epub 2008 Jun 25. http://dx.doi.org/10.1007/s12253-008-9073-5
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Makaleleri
Yazarlar

Zeynep Karakaş Bu kişi benim

Serap Erdem Kuruca Bu kişi benim

Beyza Çetin Bu kişi benim

Sabriye Karadenizli Bu kişi benim

Nilgün Akdeniz Bu kişi benim

Belkıs Atasever Bu kişi benim

Günnur Deniz Bu kişi benim

Tuğçe Aksu Uzunhan Bu kişi benim

Yayımlanma Tarihi 1 Ekim 2011
Yayımlandığı Sayı Yıl 2011 Cilt: 11 Sayı: 4

Kaynak Göster

APA Karakaş, Z., Erdem Kuruca, S., Çetin, B., Karadenizli, S., vd. (2011). Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri. Çocuk Dergisi, 11(4), 160-169. https://doi.org/10.5222/j.child.2011.160
AMA Karakaş Z, Erdem Kuruca S, Çetin B, Karadenizli S, Akdeniz N, Atasever B, Deniz G, Uzunhan TA. Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri. Çocuk Dergisi. Ekim 2011;11(4):160-169. doi:10.5222/j.child.2011.160
Chicago Karakaş, Zeynep, Serap Erdem Kuruca, Beyza Çetin, Sabriye Karadenizli, Nilgün Akdeniz, Belkıs Atasever, Günnur Deniz, ve Tuğçe Aksu Uzunhan. “Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri”. Çocuk Dergisi 11, sy. 4 (Ekim 2011): 160-69. https://doi.org/10.5222/j.child.2011.160.
EndNote Karakaş Z, Erdem Kuruca S, Çetin B, Karadenizli S, Akdeniz N, Atasever B, Deniz G, Uzunhan TA (01 Ekim 2011) Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri. Çocuk Dergisi 11 4 160–169.
IEEE Z. Karakaş, S. Erdem Kuruca, B. Çetin, S. Karadenizli, N. Akdeniz, B. Atasever, G. Deniz, ve T. A. Uzunhan, “Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri”, Çocuk Dergisi, c. 11, sy. 4, ss. 160–169, 2011, doi: 10.5222/j.child.2011.160.
ISNAD Karakaş, Zeynep vd. “Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri”. Çocuk Dergisi 11/4 (Ekim 2011), 160-169. https://doi.org/10.5222/j.child.2011.160.
JAMA Karakaş Z, Erdem Kuruca S, Çetin B, Karadenizli S, Akdeniz N, Atasever B, Deniz G, Uzunhan TA. Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri. Çocuk Dergisi. 2011;11:160–169.
MLA Karakaş, Zeynep vd. “Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri”. Çocuk Dergisi, c. 11, sy. 4, 2011, ss. 160-9, doi:10.5222/j.child.2011.160.
Vancouver Karakaş Z, Erdem Kuruca S, Çetin B, Karadenizli S, Akdeniz N, Atasever B, Deniz G, Uzunhan TA. Akut Lenfoblastik Lösemili Çocuklarda Kemoterapinin Doğal Öldürücü NK Hücreler Üzerine Etkileri. Çocuk Dergisi. 2011;11(4):160-9.